{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:18:03Z","timestamp":1786634283358,"version":"build-2736575974"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpm-2018-0360_s_999_w2aab2b8c67b1b7b1aab1c17b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erythropoietin (EPO) appears to confer neuroprotection to the injured brain. Randomized clinical trials (RCTs) have demonstrated its safety in neonates with hypoxic-ischemic encephalopathy (HIE); however, the evidence is unclear. The objective of this study was to examine the role of EPO in perinatal HIE by a systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2018-0360_s_998_w2aab2b8c67b1b7b1aab1c17b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Database search included Embase, MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Cochrane Central Register of Controlled Trials (CENTRAL). RCTs reporting a death, neurodevelopmental outcomes or brain injury were included. Two authors extracted the data independently from included studies and assessed the level of evidence (LOE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2018-0360_s_997_w2aab2b8c67b1b7b1aab1c17b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six RCTs (EPO=5 and darbepoetin \u03b1=1) involving 454 neonates were included. A trend toward a lower risk of death was identified in infants treated with EPO [EPO with or without hypothermia: five RCTs, 368 participants, relative risk (RR) 0.74, 95% confidence interval (CI) 0.47\u20131.19, LOE\u2212low; EPO without hypothermia: four RCTs, 318 participants, RR 0.89, 95% CI 0.49\u20131.32, LOE\u2212low]. EPO treatment without hypothermia compared to placebo resulted in a reduced risk of cerebral palsy (two RCTs, 230 participants, RR 0.47, 95% CI 0.27\u20130.80, LOE\u2212moderate) and moderate to severe cognitive impairment (two RCTs, 226 participants, RR 0.49, 95% CI 0.28\u20130.85, LOE\u2212moderate). A reduced risk of brain injury was identified in EPO treated infants (EPO with or without hypothermia, two RCTs, 148 participants, RR 0.70, 95% CI 0.53\u20130.92, LOE\u2212moderate).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2018-0360_s_996_w2aab2b8c67b1b7b1aab1c17b4Aa\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>EPO administration in neonates with perinatal HIE reduces the risk of brain injury, cerebral palsy and cognitive impairment. The evidence is limited to suggest its role as an adjuvant to hypothermia. Larger powered trials are underway to overcome this limitation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpm-2018-0360","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T07:51:50Z","timestamp":1551945110000},"page":"478-489","source":"Crossref","is-referenced-by-count":46,"title":["Erythropoietin in perinatal hypoxic-ischemic encephalopathy: a systematic review and meta-analysis"],"prefix":"10.1515","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-3694","authenticated-orcid":false,"given":"Abdul","family":"Razak","sequence":"first","affiliation":[{"name":"Associate Clinical Professor, Staff Neonatologist, Division of Neonatology, Department of Pediatrics , Princess Nourah Bint AbdulRahman University, King Abdullah bin Abdul Aziz University Hospital , Riyadh 13412 , Saudi Arabia"},{"name":"Department of Pediatrics , McMaster University , Hamilton, ON, L8S 4L8 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Orthopedics , Bhimrao Ambedkar University , Agra, UP , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"2023033121263846869_j_jpm-2018-0360_ref_001_w2aab2b8c67b1b7b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: when? Where? Why? Lancet 2005;365:891\u2013900.","DOI":"10.1016\/S0140-6736(05)71048-5"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_002_w2aab2b8c67b1b7b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Gonzalez FF, Miller SP. Does perinatal asphyxia impair cognitive function without cerebral palsy? Arch Dis Child Fetal Neonatal Ed 2006;91:F454\u20139.","DOI":"10.1136\/adc.2005.092445"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_003_w2aab2b8c67b1b7b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev 2013;1:Cd003311.","DOI":"10.1002\/14651858.CD003311.pub3"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_004_w2aab2b8c67b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009;361:1349\u201358.","DOI":"10.1056\/NEJMoa0900854"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_005_w2aab2b8c67b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Juul SE, Pet GC. Erythropoietin and neonatal neuroprotection. Clin Perinatol 2015;42:469\u201381.","DOI":"10.1016\/j.clp.2015.04.004"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_006_w2aab2b8c67b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Juul SE, Beyer RP, Bammler TK, McPherson RJ, Wilkerson J, Farin FM. Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampus. Pediatr Res 2009;65:485\u201392.","DOI":"10.1203\/PDR.0b013e31819d90c8"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_007_w2aab2b8c67b1b7b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641\u20137.","DOI":"10.1038\/35088074"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_008_w2aab2b8c67b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia\/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke 2005;36:1672\u20138.","DOI":"10.1161\/01.STR.0000173406.04891.8c"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_009_w2aab2b8c67b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Dame C, Juul SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 2001;79:228\u201335.","DOI":"10.1159\/000047097"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_010_w2aab2b8c67b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95:4635\u201340.","DOI":"10.1073\/pnas.95.8.4635"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_011_w2aab2b8c67b1b7b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009;124:e218\u201326.","DOI":"10.1542\/peds.2008-3553"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_012_w2aab2b8c67b1b7b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Baserga MC, Beachy JC, Roberts JK, Ward RM, Digeronimo RJ, Walsh WF, et al. Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatr Res 2015;78:315\u201322.","DOI":"10.1038\/pr.2015.101"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_013_w2aab2b8c67b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Garg B, Sharma D, Bansal A. Systematic review seeking erythropoietin role for neuroprotection in neonates with hypoxic ischemic encephalopathy: presently where do we stand. J Matern Fetal Neonatal Med 2017;31:1\u201311.","DOI":"10.1080\/14767058.2017.1366982"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_014_w2aab2b8c67b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, et al. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration. Int J Equity Health 2015;14:1.","DOI":"10.1186\/s12939-015-0219-2"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_015_w2aab2b8c67b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol 1976;33:696\u2013705.","DOI":"10.1001\/archneur.1976.00500100030012"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_016_w2aab2b8c67b1b7b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997;39:214\u201323.","DOI":"10.1111\/j.1469-8749.1997.tb07414.x"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_017_w2aab2b8c67b1b7b1ab2b1c17Aa","unstructured":"Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Psychological Corporation; 1993."},{"key":"2023033121263846869_j_jpm-2018-0360_ref_018_w2aab2b8c67b1b7b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Albers CA, Grieve AJ. Test Review: Bayley, N. (2006). Bayley Scales of Infant and Toddler Development \u2013 Third Edition. San Antonio, TX: Harcourt Assessment. Psychol Assess 2007;25:180\u201390.","DOI":"10.1177\/0734282906297199"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_019_w2aab2b8c67b1b7b1ab2b1c19Aa","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, West Sussex, UK: Wiley; 2011."},{"key":"2023033121263846869_j_jpm-2018-0360_ref_020_w2aab2b8c67b1b7b1ab2b1c20Aa","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. McMaster University, Canada: Cochrane; 2015."},{"key":"2023033121263846869_j_jpm-2018-0360_ref_021_w2aab2b8c67b1b7b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Wu YW, Mathur AM, Chang T, McKinstry RC, Mulkey SB, Mayock DE, et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial. Pediatrics 2016;137:pii: e20160191.","DOI":"10.1542\/peds.2016-0191"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_022_w2aab2b8c67b1b7b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Malla RR, Asimi R, Teli MA, Shaheen F, Bhat MA. Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. J Perinatol 2017;37:596\u2013601.","DOI":"10.1038\/jp.2017.17"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_023_w2aab2b8c67b1b7b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Avasiloaiei A, Dimitriu C, Moscalu M, Paduraru L, Stamatin M. High-dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatr Int 2013;55:589\u201393.","DOI":"10.1111\/ped.12121"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_024_w2aab2b8c67b1b7b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"El Shimi MS, Awad HA, Hassanein SMA, Gad GI, Imam SS, Shaaban HA, et al. Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings. J Matern Fetal Neonatal Med 2014;27:1295\u2013300.","DOI":"10.3109\/14767058.2013.855894"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_025_w2aab2b8c67b1b7b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Rigourd V, Kieffer F, Dommergues MA, Ayachi A, Assaf Z, Mohamed I, et al. Erythropoietin administration to preterm infants: comparison between subcutaneous and intravenous route. Arch Pediatr 2004;11:319\u201326.","DOI":"10.1016\/j.arcped.2003.12.025"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_026_w2aab2b8c67b1b7b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Lopez E, Beuchee A, Truffert P, Pouvreau N, Patkai J, Baud O, et al. Recombinant human erythropoietin in neonates: guidelines for clinical practice from the French Society of Neonatology. Arch Pediatr 2015;22:1092\u20137.","DOI":"10.1016\/j.arcped.2015.07.001"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_027_w2aab2b8c67b1b7b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"McPherson RJ, Demers EJ, Juul SE. Safety of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology 2007;91:36\u201343.","DOI":"10.1159\/000096969"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_028_w2aab2b8c67b1b7b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res 2007;61:451\u20135.","DOI":"10.1203\/pdr.0b013e3180332cec"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_029_w2aab2b8c67b1b7b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Gonzalez FF, McQuillen P, Mu D, Chang Y, Wendland M, Vexler Z, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci 2007;29:321\u201330.","DOI":"10.1159\/000105473"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_030_w2aab2b8c67b1b7b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971\u20135.","DOI":"10.1084\/jem.20021067"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_031_w2aab2b8c67b1b7b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044\u20139.","DOI":"10.1073\/pnas.051606598"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_032_w2aab2b8c67b1b7b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 2012;130:683\u201391.","DOI":"10.1542\/peds.2012-0498"},{"key":"2023033121263846869_j_jpm-2018-0360_ref_033_w2aab2b8c67b1b7b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Thayyil S, Oliveira V, Lally PJ, Swamy R, Bassett P, Chandrasekaran M, et al. Hypothermia for encephalopathy in low and middle-income countries (HELIX): study protocol for a randomised controlled trial. Trials 2017;18:432.","DOI":"10.1186\/s13063-017-2165-3"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpme.2019.47.issue-4\/jpm-2018-0360\/jpm-2018-0360.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2018-0360\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2018-0360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T06:56:14Z","timestamp":1680332174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2018-0360\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,2,14]]},"published-print":{"date-parts":[[2019,5,27]]}},"alternative-id":["10.1515\/jpm-2018-0360"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2018-0360","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735145137.793577778","asserted-by":"object"}]},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,21]]}}}